Wolverine Stack
BPC-157 + TB-500 Recovery Stack
A user-named pairing of BPC-157 and TB-500, each studied mostly in animals
The Wolverine Stack is a community name for using BPC-157 and TB-500 together. It refers to the X-Men character known for healing quickly. Each peptide has been studied on its own, almost entirely in animals: BPC-157 has consistent rodent data on tendon, muscle and gut healing plus three small uncontrolled human pilots, while FDA says it has found no human exposure data for the TB-500 fragment. As of October 2026, no study has tested the combination. The closest human data come from a 2021 retrospective series of 16 knee patients, some given BPC-157 alone and some given BPC-157 with thymosin beta-4, with no control group. Neither peptide is approved as a drug, and WADA's 2026 Prohibited List bans both at all times (BPC-157 under S0, TB-500 under S2.3).
Key Benefits
Mechanism of Action
The proposed mechanisms come from separate animal and cell studies of each peptide, not from studies of the combination. For BPC-157, rat and cell-culture work points to more VEGF/VEGFR2 signaling (angiogenesis, the growth of new blood vessels), changes in nitric oxide signaling, and FAK-paxillin activity linked to cell migration. TB-500 is a synthetic copy of the actin-binding region of thymosin beta-4 (Ac-LKKTETQ, residues 17-23). In animal studies of the full-length protein, this region is linked to cell migration and angiogenesis, and the full protein was linked to less fibrosis (scarring). How much of that carries over to the seven-residue fragment is unknown. Vendors and users describe the pair as synergistic, with BPC-157 handling local vascular repair and TB-500 working throughout the body. That idea is pieced together from the separate mechanisms. No study has tested whether the two peptides add to each other, or measured where either one goes in people.
Dosing Guidelines
Typical Dose
BPC-157: 250-500 mcg/day + TB-500: 2-2.5 mg 2x/week
Frequency
BPC-157 daily, TB-500 twice weekly
Duration
4-8 weeks
Note: These figures follow vendor and community guidance. No trial has tested any dose of the combination, and no human dose has been tested for the TB-500 fragment. Users on peptide forums commonly describe BPC-157 at 250-500 mcg/day by subcutaneous injection, sometimes split into two doses, alongside TB-500 at 2-2.5 mg twice weekly. Some report 2.5-5 mg of TB-500 twice weekly, or 500 mcg of each peptide twice daily. Many inject BPC-157 near the injury site and TB-500 in the abdomen. No human study has compared injection sites, and the claim that TB-500's site doesn't matter has no human absorption data behind it. Vendor guidance moves TB-500 to monthly maintenance after a 4-6 week loading phase. The 4-8 week duration is also vendor guidance; on forums, many users say to allow 8 weeks or more, and many report no change.
Research & Studies
How BPC-157 is studied for tendon, ligament and other tissue healing, mostly in rodents, and how users report using it for recovery.
Read Full ResearchWhat the TB-500 research shows on cell migration and wound repair, most of it from animal studies of full-length thymosin beta-4.
Read Full ResearchCompares the BPC-157 and TB-500 research on tissue repair, inflammation, reported dosing and safety signals, most of it from animal studies.
Read Full ResearchSide effects, safety signals and contraindications reported across common research peptides, with the evidence type behind each.
Read Full ResearchPotential Side Effects
Reported side effects may include:
- - No safety data on the combination; FDA has found no human exposure data for the TB-500 fragment
- - BPC-157: no adverse events reported in 3 small human pilots (30 people); no safety study has run past 6 weeks
- - Injection-site pain, redness or swelling (user reports)
- - Fatigue, flushing or low mood, mostly in the first week (user reports of the combination)
- - Nausea or dizziness (vendor lists for BPC-157; not traced to a study)
- - Head rush after TB-500 injection (vendor lists)
This information is for research purposes only. Always consult with a healthcare professional.
Popular Stacking Options
Wolverine Stack + Ipamorelin
Some users add ipamorelin, a growth hormone secretagogue, aiming to pair repair effects with overnight growth hormone release; the three-peptide version is sometimes called the 'Full Send Stack'. No study has tested it. Ipamorelin's own human data are limited to one IV dosing study and a Phase 2 trial that missed its primary endpoint.
Shop this stackWolverine Stack + GHK-Cu
Some users add GHK-Cu for skin and connective-tissue goals, based on its collagen and wound-healing research. Its human data come from small topical cream studies; there are no human trials of injected GHK-Cu, and none of it combined with BPC-157 or TB-500.
Shop this stackFrequently Asked Questions
Why is it called the Wolverine Stack?
It's a community nickname that refers to the X-Men character Wolverine, known for healing quickly. BPC-157 with TB-500 is one of the most commonly discussed recovery pairings on peptide forums, and vendors market it as synergistic. As of October 2026, no study has tested whether the two work better together than either one alone.
Can I inject both peptides at the same time?
Users commonly report taking both in the same session, drawn into separate syringes, with BPC-157 injected near the injury site and TB-500 under the skin elsewhere, often the abdomen. That's community practice, not a tested protocol. No study has looked at giving the two together or compared injection sites for either peptide.
How quickly will I see results from the Wolverine Stack?
No study has measured a timeline for the combination. On peptide forums, reports vary widely: some users describe less pain within 1-2 weeks, many say to allow 8 weeks or more, and many report no change. These are self-reports from people who chose to post, and they vary with the type of injury and the quality of the product.
Is the Wolverine Stack safe for long-term use?
Long-term safety in humans is unknown, for each peptide and for the combination. BPC-157's human data are three small pilots with 30 people in total. They reported no adverse events but weren't designed to catch rare or delayed problems, and the longest animal safety studies lasted 6 weeks. FDA says it has found no human exposure data for the TB-500 fragment. The 4-8 week protocols and monthly TB-500 maintenance come from vendor and community guidance, not trials. Extended use should include regular health monitoring.
Ready to Purchase Wolverine Stack?
Get pharmaceutical-grade Wolverine Stack from Simple Peptide with 99%+ purity, third-party lab testing, and same-day dispatch.
Buy Wolverine Stack Now